• In May 2026, IDEXX Laboratories expanded its Fecal Dx antigen testing to detect taeniid tapeworm species and integrated the SDMA renal biomarker into Catalyst CLIPs, with the upgraded services rolling out to US and Canadian reference lab customers at no additional cost from late June.
• These enhancements broaden IDEXX’s diagnostic menu in parasitology and kidney assessment, potentially increasing the clinical relevance and stickiness of its veterinary testing platforms.
• We’ll now examine how adding SDMA to Catalyst CLIPs may influence IDEXX’s investment narrative around recurring diagnostics and innovation.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

IDEXX Laboratories Investment Narrative Recap

To be a shareholder in IDEXX, you need to believe the company can keep deepening its recurring diagnostic revenue base despite softer U.S. vet visit trends and rising competition. The recent SDMA and Fecal Dx upgrades strengthen IDEXX’s value proposition per test, but they do not materially change the near term dependence on instrument placements and clinic utilization, which still look like the key swing factor and the biggest operational risk.

Among recent developments, the integration of the SDMA renal biomarker into Catalyst CLIPs is most relevant here, because it directly supports higher diagnostic intensity per visit and reinforces the installed base of premium chemistry analyzers. If clinics adopt SDMA as a routine kidney function marker within Catalyst profiles, that could modestly support the recurring consumables catalyst that many investors are watching, especially as growth in new instrument placements is expected to moderate.

Yet, against this promising test expansion, the risk that softer U.S. visit trends and price sensitivity could still weigh on IDEXX’s premium diagnostics is something investors should be aware of and...

IDEXX Laboratories' narrative projects $5.2 billion revenue and $1.3 billion earnings by 2028. This requires 8.8% yearly revenue growth and roughly a $300 million earnings increase from $985.7 million today.

Uncover how IDEXX Laboratories' forecasts yield a $750.23 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts paint a more cautious picture, assuming revenue of about US$5.5 billion and earnings of roughly US$1.5 billion by 2029, so if you lean toward their view you are effectively betting that pressures on vet visits and pricing will matter more than new offerings like enhanced SDMA and Fecal Dx, while other investors might see these same upgrades as reasons to revisit those conservative assumptions.

Explore 3 other fair value estimates on IDEXX Laboratories - why the stock might be worth as much as 49% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IDEXX Laboratories research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IDEXX Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEXX Laboratories' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.